PRT2527

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies

Arms / Cohorts

Experimental:PRT2527 Monotherapy in Lymphoid Malignancies

Accepting patients

Experimental:PRT2527/Zanubrutinib Combination in Lymphoid Malignancies

Accepting patients

Experimental:PRT2527 Monotherapy in Myeloid Malignancies

Accepting patients

Experimental:PRT2527/Venetoclax Combination in Myeloid Malignancies

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.